FIG 4.

Impact of prior therapy with AL on ex vivo drug sensitivities. Samples were categorized based on the time since patients had received a prior therapy with AL, and geometric mean IC₅₀s were calculated. The number of samples in each category is indicated by N. Values for each drug were compared with those for children who did not receive prior therapy within 70 days (over 70), and comparisons with P values of <0.05 (*), <0.01 (**), and <0.001 (***) in univariate analysis are labeled. With multivariate analysis, only the median piperaquine IC₅₀ for 51 to 70 days since prior treatment was statistically significant.